Theravance Biopharma, Inc. (TBPH) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $53.74M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.00× | Operating cash flow / net income. Period ending 2026-06-30. $53.74M ÷ $53.81M ≈ 1.00× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | 53.74M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 104.31M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 53.81M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $53.74M | (m) | (m) | $104.31M | (m) | $53.81M | (m) | (m) | (m) | 1.00× |
| 2026-03-31 | (m) | (m) | $268.78M | (m) | (m) | $109.78M | (m) | $114.54M | (m) | (m) | (m) | 2.35× |
| 2025-12-31 | (m) | (m) | $238.54M | (m) | (m) | $107.46M | (m) | $105.89M | (m) | (m) | (m) | 2.25× |
| 2025-09-30 | (m) | (m) | $243.70M | (m) | (m) | $80.33M | (m) | $29.34M | (m) | (m) | (m) | 8.31× |
| 2025-06-30 | (m) | (m) | $245.01M | (m) | (m) | $77.20M | (m) | $13.03M | (m) | (m) | (m) | 18.80× |
| 2025-03-31 | (m) | (m) | $32.53M | (m) | (m) | $65.27M | (m) | $-58.33M | (m) | (m) | (m) | -0.56× |
| 2024-12-31 | (m) | (m) | $-11.54M | (m) | (m) | $64.38M | (m) | $-56.42M | (m) | (m) | (m) | 0.20× |
| 2024-09-30 | (m) | (m) | $-11.49M | (m) | (m) | $63.19M | (m) | $-49.40M | (m) | (m) | (m) | 0.23× |
| 2024-06-30 | (m) | (m) | $-8.78M | (m) | (m) | $62.02M | (m) | $-45.65M | (m) | (m) | (m) | 0.19× |
| 2024-03-31 | (m) | (m) | $-16.80M | (m) | (m) | $61.51M | (m) | $-44.77M | (m) | (m) | (m) | 0.38× |
| 2023-12-31 | (m) | (m) | $-27.00M | (m) | (m) | $57.42M | (m) | $-55.19M | (m) | (m) | (m) | 0.49× |
| 2023-09-30 | (m) | (m) | $-150.20M | (m) | (m) | $54.51M | (m) | $-57.05M | (m) | (m) | (m) | 2.63× |
| 2023-06-30 | (m) | (m) | $-169.85M | (m) | (m) | $51.27M | (m) | $868.54M | (m) | (m) | (m) | -0.20× |
| 2023-03-31 | (m) | (m) | $-172.14M | (m) | (m) | $48.57M | (m) | $875.99M | (m) | (m) | (m) | -0.20× |
| 2022-12-31 | (m) | (m) | $-186.99M | (m) | (m) | $51.35M | (m) | $872.13M | (m) | (m) | (m) | -0.21× |
| 2022-09-30 | (m) | (m) | $-105.37M | (m) | (m) | $51.64M | (m) | $850.46M | (m) | (m) | (m) | -0.12× |
| 2022-06-30 | (m) | (m) | $-128.68M | (m) | (m) | $52.39M | (m) | $-101.48M | (m) | (m) | (m) | 1.27× |
| 2022-03-31 | (m) | (m) | $-164.06M | (m) | (m) | $54.25M | (m) | $-145.69M | (m) | (m) | (m) | 1.13× |
| 2021-12-31 | (m) | (m) | $-207.86M | (m) | (m) | $55.31M | (m) | $-199.43M | (m) | (m) | (m) | 1.04× |
| 2021-09-30 | (m) | (m) | $-230.35M | (m) | (m) | $59.09M | (m) | $-225.83M | (m) | (m) | (m) | 1.02× |
| 2021-06-30 | (m) | (m) | $-261.93M | (m) | (m) | $64.16M | (m) | $-264.16M | (m) | (m) | (m) | 0.99× |
| 2021-03-31 | (m) | (m) | $-265.17M | (m) | (m) | $66.25M | (m) | $-274.64M | (m) | (m) | (m) | 0.97× |
| 2020-12-31 | (m) | (m) | $-250.40M | (m) | (m) | $71.86M | (m) | $-278.02M | (m) | (m) | (m) | 0.90× |
| 2020-09-30 | (m) | (m) | $-249.83M | (m) | (m) | $82.63M | (m) | $-285.19M | (m) | (m) | (m) | 0.88× |
| 2020-06-30 | (m) | (m) | $-217.42M | (m) | (m) | $76.80M | (m) | $-269.98M | (m) | (m) | (m) | 0.81× |
| 2020-03-31 | (m) | (m) | $-212.10M | (m) | (m) | $87.94M | (m) | $-246.93M | (m) | (m) | (m) | 0.86× |
| 2019-12-31 | (m) | (m) | $-238.20M | (m) | (m) | $73.41M | (m) | $-236.46M | (m) | (m) | (m) | 1.01× |
| 2019-09-30 | (m) | (m) | $-226.02M | (m) | (m) | $59.65M | (m) | $-221.03M | (m) | (m) | (m) | 1.02× |
| 2019-06-30 | (m) | (m) | $-230.38M | (m) | (m) | $60.06M | (m) | $-222.04M | (m) | (m) | (m) | 1.04× |
| 2019-03-31 | (m) | (m) | $-243.88M | (m) | (m) | $57.39M | (m) | $-223.02M | (m) | (m) | (m) | 1.09× |
| 2018-12-31 | (m) | (m) | $-112.87M | (m) | (m) | $60.37M | (m) | $-215.52M | (m) | (m) | (m) | 0.52× |
| 2018-09-30 | (m) | (m) | $-104.89M | (m) | (m) | $49.15M | (m) | $-252.26M | (m) | (m) | (m) | 0.42× |
| 2018-06-30 | (m) | (m) | $-118.21M | (m) | (m) | $40.59M | (m) | $-259.70M | (m) | (m) | (m) | 0.46× |
| 2018-03-31 | (m) | (m) | $-101.20M | (m) | (m) | $20.62M | (m) | $-285.17M | (m) | (m) | (m) | 0.35× |
| 2017-12-31 | (m) | (m) | $-201.05M | (m) | (m) | $15.39M | (m) | $-285.40M | (m) | (m) | (m) | 0.70× |
| 2017-09-30 | (m) | (m) | $-184.96M | (m) | (m) | $16.56M | (m) | $-265.82M | (m) | (m) | (m) | 0.70× |
| 2017-06-30 | (m) | (m) | $-135.10M | (m) | (m) | $31.36M | (m) | $-232.90M | (m) | (m) | (m) | 0.58× |
| 2017-03-31 | (m) | (m) | $-122.71M | (m) | (m) | $33.33M | (m) | $-213.84M | (m) | (m) | (m) | 0.57× |
| 2016-12-31 | $-101.12M | (m) | $-98.99M | $2.13M | (m) | $48.65M | (m) | $-190.67M | (m) | (m) | -207.87% | 0.52× |
| 2016-09-30 | (m) | (m) | $-104.62M | (m) | (m) | $46.85M | (m) | $-168.16M | (m) | (m) | (m) | 0.62× |
| 2016-06-30 | $-126.78M | (m) | $-124.17M | $2.60M | (m) | $38.47M | (m) | $-181.52M | (m) | (m) | -329.53% | 0.68× |
| 2016-03-31 | $-141.33M | (m) | $-138.65M | $2.67M | (m) | $40.13M | (m) | $-181.90M | (m) | (m) | -352.13% | 0.76× |
| 2015-12-31 | $-171.50M | (m) | $-168.86M | $2.65M | (m) | $42.13M | (m) | $-182.22M | (m) | (m) | -407.12% | 0.93× |
| 2015-09-30 | $-180.46M | (m) | $-177.65M | $2.81M | (m) | $39.67M | (m) | $-201.70M | (m) | (m) | -454.94% | 0.88× |
| 2015-06-30 | $-184.64M | (m) | $-182.04M | $2.59M | (m) | $35.30M | (m) | $-208.88M | (m) | (m) | -522.99% | 0.87× |
| 2015-03-31 | $-189.01M | (m) | $-186.87M | $2.14M | (m) | $31.14M | (m) | $-219.49M | (m) | (m) | -606.90% | 0.85× |
| 2014-12-31 | $-178.26M | (m) | $-175.16M | $3.11M | (m) | $11.69M | (m) | $-237.04M | (m) | (m) | -1525.17% | 0.74× |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-123.69M | (m) | $-120.96M | $2.73M | (m) | $226.00K | (m) | $-156.28M | (m) | (m) | -54731.42% | 0.77× |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $-121.70M | (m) | $-119.11M | $2.59M | (m) | $130.15M | (m) | $-9.57M | (m) | (m) | -93.51% | 12.44× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |